ATE319432T1 - Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen - Google Patents

Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen

Info

Publication number
ATE319432T1
ATE319432T1 AT01998077T AT01998077T ATE319432T1 AT E319432 T1 ATE319432 T1 AT E319432T1 AT 01998077 T AT01998077 T AT 01998077T AT 01998077 T AT01998077 T AT 01998077T AT E319432 T1 ATE319432 T1 AT E319432T1
Authority
AT
Austria
Prior art keywords
submicroparticle
suspensions
producing
pharmaceutical substances
solvent
Prior art date
Application number
AT01998077T
Other languages
English (en)
Inventor
James E Kipp
Joseph Chung Tak Wong
Mark J Doty
Christine L Rebbeck
Sean Brynjelsen
Jane Werling
Rajaram Sriram
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/874,799 external-priority patent/US6607784B2/en
Priority claimed from US09/953,979 external-priority patent/US6951656B2/en
Priority claimed from US10/035,821 external-priority patent/US6977085B2/en
Priority claimed from US10/021,692 external-priority patent/US6884436B2/en
Application filed by Baxter Int filed Critical Baxter Int
Application granted granted Critical
Publication of ATE319432T1 publication Critical patent/ATE319432T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
AT01998077T 2000-12-22 2001-12-20 Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen ATE319432T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US25816000P 2000-12-22 2000-12-22
US09/874,799 US6607784B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US09/874,637 US6869617B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US09/874,499 US7037528B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US09/953,979 US6951656B2 (en) 2000-12-22 2001-09-17 Microprecipitation method for preparing submicron suspensions
US10/035,821 US6977085B2 (en) 2000-12-22 2001-10-19 Method for preparing submicron suspensions with polymorph control
US10/021,692 US6884436B2 (en) 2000-12-22 2001-12-12 Method for preparing submicron particle suspensions

Publications (1)

Publication Number Publication Date
ATE319432T1 true ATE319432T1 (de) 2006-03-15

Family

ID=27567644

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998077T ATE319432T1 (de) 2000-12-22 2001-12-20 Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen

Country Status (16)

Country Link
EP (2) EP1642571A3 (de)
JP (1) JP4376518B2 (de)
CN (1) CN100512798C (de)
AT (1) ATE319432T1 (de)
AU (2) AU2002249836B2 (de)
BR (1) BR0116377A (de)
CA (1) CA2431705C (de)
DE (1) DE60117873T2 (de)
DK (1) DK1347747T3 (de)
ES (1) ES2260337T3 (de)
HU (1) HUP0501030A3 (de)
IL (1) IL156310A0 (de)
MX (1) MXPA03005496A (de)
NO (1) NO20032860L (de)
NZ (1) NZ526608A (de)
WO (1) WO2002055059A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
AU2004234003A1 (en) * 2003-04-29 2004-11-11 Baxter International Inc. Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
WO2004112747A2 (en) 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
CA2532837A1 (en) * 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical particles by controlled phase separation
KR20060052849A (ko) * 2003-08-06 2006-05-19 에자이 가부시키가이샤 약물 초미립자의 제조 방법 및 제조 장치
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
WO2005055983A2 (en) * 2003-12-09 2005-06-23 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
CN1913871A (zh) * 2004-01-29 2007-02-14 巴克斯特国际公司 用于提高中枢神经***投递的抗-逆转录病毒药剂的纳米悬浮液
HUE028288T2 (en) * 2004-03-31 2016-12-28 Toyama Chemical Co Ltd A fine dispersion of a low solubility drug and a process for producing it
RU2006144851A (ru) 2004-06-15 2008-06-20 Бакстер Интернэшнл Инк. (Us) Применение терапевтических средств ex-vivo в виде твердых микрочастиц
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
MX2007011494A (es) * 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones inyectables de compuestos inmunosupresores nanoparticulados.
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
WO2007059515A2 (en) * 2005-11-15 2007-05-24 Baxter International, Inc. Compositions of lipoxygenase inhibitors
ES2447465T3 (es) 2008-03-05 2014-03-12 Baxter International Inc. Partículas de superficie modificada y métodos para la administración dirigida de fármacos
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
AU2011232103B2 (en) 2010-03-22 2013-10-24 Instillo Gmbh Method and device for producing microparticles or nanoparticles
CN102384973B (zh) * 2011-08-10 2014-09-10 华南理工大学 快速定量检测羟甲基糠醛的免疫层析试纸条及其制备方法
CN102268103B (zh) * 2011-09-02 2013-06-05 中国海洋大学 一种壳聚糖醋酸盐的制备方法
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients
CN103212079A (zh) * 2013-04-26 2013-07-24 陆媛 一种预防和/或治疗感冒的含服药物组合物及其应用
CN104905262B (zh) * 2015-05-29 2017-12-22 湖北省农业科学院农产品加工与核农技术研究所 一种制备虫草灵芝复合制剂的方法
KR101725508B1 (ko) * 2015-07-31 2017-04-11 국방과학연구소 헥사나이트로스틸벤 입자의 제조 방법과 그 장치
CN105969316B (zh) * 2016-06-03 2020-11-10 宁海德宝立新材料有限公司 一种用于热敷的相变储热复合材料
CA3030308C (en) 2016-07-29 2022-04-05 The Board Of Trustees Of Western Michigan University Magnetic nanoparticle-based gyroscopic sensor
CN108031142A (zh) * 2017-12-13 2018-05-15 上海合全药物研发有限公司 一种简化的利用湿磨来制备大量微晶种的装置及方法
CN115349630A (zh) * 2022-06-20 2022-11-18 海宁凤鸣叶绿素有限公司 水分散性叶黄素微囊粉的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) * 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
EP0461930B1 (de) * 1990-06-15 1995-09-13 Merck & Co. Inc. Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
FI973804A (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
CA2317106C (en) * 1997-12-31 2004-11-23 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
US8415329B1 (en) * 1998-05-29 2013-04-09 Jagotec Ag Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations
NZ505245A (en) * 1998-07-17 2001-12-21 Janssen Pharmaceutica Nv Pharmaceutical compositions of itraconazole and a water-soluble polymer to treat fungal infection
US6497905B1 (en) * 1999-03-24 2002-12-24 R.P. Scherer Technologies, Inc. Aqueous solubility pharmaceutical formulations
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법

Also Published As

Publication number Publication date
IL156310A0 (en) 2004-01-04
AU2002249836B2 (en) 2006-12-14
NO20032860L (no) 2003-08-21
EP1347747B1 (de) 2006-03-08
CN100512798C (zh) 2009-07-15
CA2431705C (en) 2010-10-05
JP2004538249A (ja) 2004-12-24
WO2002055059A3 (en) 2002-09-06
EP1642571A3 (de) 2007-06-27
MXPA03005496A (es) 2004-05-14
CN1505503A (zh) 2004-06-16
HUP0501030A2 (en) 2007-02-28
ES2260337T3 (es) 2006-11-01
DE60117873T2 (de) 2006-08-24
CA2431705A1 (en) 2002-07-18
NO20032860D0 (no) 2003-06-20
NZ526608A (en) 2006-06-30
DE60117873D1 (de) 2006-05-04
JP4376518B2 (ja) 2009-12-02
WO2002055059A2 (en) 2002-07-18
AU2006201943A1 (en) 2006-06-01
BR0116377A (pt) 2005-12-13
DK1347747T3 (da) 2006-04-10
HUP0501030A3 (en) 2008-04-28
EP1347747A2 (de) 2003-10-01
EP1642571A2 (de) 2006-04-05

Similar Documents

Publication Publication Date Title
ATE319432T1 (de) Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen
DE60222734D1 (de) Mikropartikel und Verfahren zur deren Herstellung
DE60009326D1 (de) Verfahren zur herstellung von silicoaluminophosphat-molekularsieben
DE69002905D1 (de) Verfahren zur Herstellung von lipidischen Mikropartikeln.
ATE353081T1 (de) Verfahren zur herstellung von duloxetin und deren verwendeten zwischenprodukten
ATE256458T1 (de) Verfahren zur mikroverkapselung von wasserlöslichen substanzen
DE60135296D1 (de) Verbessertes Verfahren und Methode zur Herstellung von asymmetrischen monofunktionalisierten Indocyaninmarkern sowie erhaltene Verbindungen
DE68927669T2 (de) Verfahren zur herstellung von in lösungsmitteln verdünnbaren mikroträgern
DE60227630D1 (de) Verfahren zur Herstellung von Fullerene
ATE298747T1 (de) Verfahren zur herstellung von 5- hydroxybenzo(b)thiophen-3-carbonsäure
ATE440846T1 (de) Verfahren zur herstellung von chloriden von phthalocyaninderivaten, die wenigstens eine quaternäre ammoniumgruppe enthalten
ATE275149T1 (de) Verfahren zur herstellung von taxanderivaten
ATE269314T1 (de) Verfahren zur herstellung von (2r, 3s)-amino-1,2- oxiran
ATE317259T1 (de) Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
YU59401A (sh) Postupak za proizvodnju alendronske kiseline
ATE384067T1 (de) Verfahren zur herstellung von 3-cephemderivaten
DE69618496D1 (de) Verfahren zur Derivatisierung von Polyglukosaminen
DE60207042D1 (de) Verfahren zur herstellung einer wässrigen zellulosederivat-dispersion
ATE285393T1 (de) Verfahren zur herstellung von (r)-2-brom-3- phenylpropionsäure
ATE301637T1 (de) Verfahren zur herstellung von n-geschützten azetidin-2-carbonsäuren
ATE360086T1 (de) Verfahren zur herstellung von avermectinderivaten
ATE171937T1 (de) Verfahren zur herstellung von diazomethanderivaten
DE60031315D1 (de) Verfahren zur Herstellung von Derivaten von i(1,5-Diaryl)pyrazol-3-ylöpropansäure
DE60027754D1 (de) Verfahren zur herstellung von photolumineszenten polarisatoren
ATE305445T1 (de) Verfahren zur herstellung von 2,3-pentandion

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1347747

Country of ref document: EP